tradingkey.logo

Vivos Therapeutics Inc

VVOS
1.970USD
-0.010-0.51%
Close 12/19, 16:00ETQuotes delayed by 15 min
16.29MMarket Cap
LossP/E TTM

Vivos Therapeutics Inc

1.970
-0.010-0.51%

More Details of Vivos Therapeutics Inc Company

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.

Vivos Therapeutics Inc Info

Ticker SymbolVVOS
Company nameVivos Therapeutics Inc
IPO dateDec 11, 2020
CEOHuntsman (R. Kirk)
Number of employees109
Security typeOrdinary Share
Fiscal year-endDec 11
Address7921 Southpark Plaza,
CityLITTLETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80120
Phone18669084867
Websitehttps://vivos.com/
Ticker SymbolVVOS
IPO dateDec 11, 2020
CEOHuntsman (R. Kirk)

Company Executives of Vivos Therapeutics Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Bradford K. (Brad) Amman
Mr. Bradford K. (Brad) Amman
Chief Financial Officer
Chief Financial Officer
80.00
--
Mr. R. Kirk Huntsman
Mr. R. Kirk Huntsman
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Ralph E. Green, DDS
Dr. Ralph E. Green, DDS
Independent Director
Independent Director
--
--
Ms. Anja B. Krammer
Ms. Anja B. Krammer
Independent Director
Independent Director
--
--
Mr. Mark F. Lindsay
Mr. Mark F. Lindsay
Independent Director
Independent Director
--
--
Dr. Matthew Thompson, M.D.
Dr. Matthew Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Leonard J. (Lenny) Sokolow, CPA
Mr. Leonard J. (Lenny) Sokolow, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Bradford K. (Brad) Amman
Mr. Bradford K. (Brad) Amman
Chief Financial Officer
Chief Financial Officer
80.00
--
Mr. R. Kirk Huntsman
Mr. R. Kirk Huntsman
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Ralph E. Green, DDS
Dr. Ralph E. Green, DDS
Independent Director
Independent Director
--
--
Ms. Anja B. Krammer
Ms. Anja B. Krammer
Independent Director
Independent Director
--
--
Mr. Mark F. Lindsay
Mr. Mark F. Lindsay
Independent Director
Independent Director
--
--
Dr. Matthew Thompson, M.D.
Dr. Matthew Thompson, M.D.
Independent Director
Independent Director
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Appliance sales to integrated providers
1.03M
26.91%
Center revenue
857.00K
22.43%
Sleep testing services
844.00K
22.09%
Sponsorship/seminar
608.00K
15.92%
Billing intelligence service
190.00K
4.97%
Other
293.00K
7.67%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Appliance sales to integrated providers
1.03M
26.91%
Center revenue
857.00K
22.43%
Sleep testing services
844.00K
22.09%
Sponsorship/seminar
608.00K
15.92%
Billing intelligence service
190.00K
4.97%
Other
293.00K
7.67%

Shareholding Stats

Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Skaff (Michael C.)
9.21%
Luo (Dawei)
6.36%
V-CO Investors, L.L.C.
5.72%
Armistice Capital LLC
2.78%
Intracoastal Capital, L.L.C.
2.54%
Other
73.37%
Shareholders
Shareholders
Proportion
Skaff (Michael C.)
9.21%
Luo (Dawei)
6.36%
V-CO Investors, L.L.C.
5.72%
Armistice Capital LLC
2.78%
Intracoastal Capital, L.L.C.
2.54%
Other
73.37%
Shareholder Types
Shareholders
Proportion
Individual Investor
16.39%
Corporation
8.27%
Hedge Fund
5.48%
Investment Advisor
4.48%
Investment Advisor/Hedge Fund
1.08%
Venture Capital
0.92%
Other
63.38%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
53
815.76K
10.87%
-21.74K
2025Q2
60
2.22M
33.10%
+944.35K
2025Q1
65
1.44M
22.49%
+733.38K
2024Q4
63
1.28M
22.00%
+869.59K
2024Q3
68
786.28K
18.32%
+305.75K
2024Q2
66
387.48K
12.85%
-179.65K
2024Q1
67
465.07K
19.33%
-62.17K
2023Q4
69
458.43K
25.00%
-105.78K
2023Q3
76
380.33K
31.77%
-57.99K
2023Q2
78
390.56K
32.63%
-94.20K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Skaff (Michael C.)
828.00K
11.03%
+828.00K
--
Jun 09, 2025
Luo (Dawei)
572.02K
7.62%
+572.02K
--
Jul 08, 2025
V-CO Investors, L.L.C.
514.50K
6.86%
--
--
Jun 09, 2025
Armistice Capital LLC
250.28K
3.33%
+250.28K
--
Sep 30, 2024
Intracoastal Capital, L.L.C.
228.61K
3.05%
+228.61K
--
Dec 30, 2024
The Vanguard Group, Inc.
42.63K
0.57%
--
--
Jun 30, 2025
Ionic Ventures LLC
83.00K
1.11%
+83.00K
--
Sep 30, 2024
Huntsman (Ronald Kirk)
73.06K
0.97%
--
--
Sep 08, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Date
Type
Ratio
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1
Oct 26, 2023
Merger
25→1

FAQs

Who are the top five shareholders of Vivos Therapeutics Inc?

The top five shareholders of Vivos Therapeutics Inc are:
Skaff (Michael C.) holds 828.00K shares, accounting for 11.03% of the total shares.
Luo (Dawei) holds 572.02K shares, accounting for 7.62% of the total shares.
V-CO Investors, L.L.C. holds 514.50K shares, accounting for 6.86% of the total shares.
Armistice Capital LLC holds 250.28K shares, accounting for 3.33% of the total shares.
Intracoastal Capital, L.L.C. holds 228.61K shares, accounting for 3.05% of the total shares.

What are the top three shareholder types of Vivos Therapeutics Inc?

The top three shareholder types of Vivos Therapeutics Inc are:
Skaff (Michael C.)
Luo (Dawei)
V-CO Investors, L.L.C.

How many institutions hold shares of Vivos Therapeutics Inc (VVOS)?

As of 2025Q3, 53 institutions hold shares of Vivos Therapeutics Inc, with a combined market value of approximately 815.76K, accounting for 10.87% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -22.23%.

What is the biggest source of revenue for Vivos Therapeutics Inc?

In FY2025Q2, the Appliance sales to integrated providers business generated the highest revenue for Vivos Therapeutics Inc, amounting to 1.03M and accounting for 26.91% of total revenue.
KeyAI